Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Pembrolizumab or Enfortumab Vedotin + Pembrolizumab in Muscle-Invasive Bladder Cancer
NCT03924895Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
A Phase 3 trial of pembrolizumab, enfortumab vedotin in muscle-invasive bladder cancer (MIBC), sponsored by Merck & Co.. Started Jul 2019; status: active, not recruiting.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03924895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924895.